1
00:00:00,000 --> 00:00:05,875
Pemvidutide research shows why a trial can have more than one important result.

2
00:00:05,875 --> 00:00:10,958
The IMPACT study assessed liver inflammation and scarring as distinct outcomes.

3
00:00:10,958 --> 00:00:16,833
This randomized phase two study enrolled 212 people with biopsy-confirmed MASH and moderate-to-advanced

4
00:00:16,833 --> 00:00:21,917
fibrosis. Its published analysis assessed two primary endpoints at 24 weeks.

5
00:00:21,917 --> 00:00:26,583
Pemvidutide met the endpoint of MASH resolution without worsening fibrosis.

6
00:00:26,583 --> 00:00:33,667
It did not meet the separate endpoint of fibrosis improvement without worsening MASH at that time.

7
00:00:33,667 --> 00:00:37,167
Both findings belong in the summary.

8
00:00:37,167 --> 00:00:43,417
Longer follow-up matters, and one favorable biopsy endpoint does not establish prevention of liver

9
00:00:43,417 --> 00:00:46,917
failure or overall long-term safety.